Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NeuroPace (NPCE) EBITDA Margin (2020 - 2025)

NeuroPace (NPCE) has 6 years of EBITDA Margin data on record, last reported at 6.65% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1037.0% year-over-year to 6.65%; the TTM value through Dec 2025 reached 16.34%, up 1411.0%, while the annual FY2025 figure was 16.34%, 1078.0% up from the prior year.
  • EBITDA Margin reached 6.65% in Q4 2025 per NPCE's latest filing, up from 9.51% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6.65% in Q4 2025 and bottomed at 129.01% in Q2 2022.
  • Average EBITDA Margin over 5 years is 57.45%, with a median of 52.25% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -6158bps in 2022, then skyrocketed 7375bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 100.01% in 2021, then increased by 15bps to 85.39% in 2022, then surged by 60bps to 34.42% in 2023, then surged by 51bps to 17.02% in 2024, then surged by 61bps to 6.65% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6.65% in Q4 2025, 9.51% in Q3 2025, and 29.01% in Q2 2025.